thought call
commerci trend solid near-term focu baricitinib approv follow
strong includ solid trend diabet expect near-term focu shift
baricitinib specif viabil mg dose view despit unfavor
vote risk/benefit higher dose still view approv mg
like given comment adcomm treatment option refractori patient
addit eu/jpn approv mg dose seemingli straightforward lilli
alreadi conced extens post-market studi support fda approv
lly/inci thought baricitinib ad com discuss vote question
beyond baricitinib galcanezumab add lilli alreadi differenti
portfolio newer product though like anti-cgrp product approv
migrain contrast mani us biopharma lilli view doesnt
larger deal augment top-lin growth pipelin spin-off/sal
elanco occur wed expect good upsid margin growth perspect
overal think lilli growth profil remain compel long-term
guidanc look quit beatabl support ow rate pt
headach portfolio like anchor next leg growth lilli could leg
competit novel migrain market galcanezumab lasmiditan
present portfolio approach payer contract like critic secur
commerci success given multipl product space larg potenti
patient popul done lot work migrain space past
month recent take migrain market see amgn/lli takeaway
view rimegep thought ubrogep oral
cgrp phase data migrain
oral sema competit fulli appreci view diabet remain
competit trulic weve model grow
model chang see non-gaap ep non-
gaap ep page detail
quarterli annual ep usd
consensu number thomson reuter receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
return equiti ttm
link barclay live interact chart
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight exit yz period
new commerci stage portfolio attract diabet
oncolog immunolog asset model
forecast mid single-digit sale low double-digit
ep growth major
pharma averag execut product
cadenc think current multipl
faster expect commerci launch
expect jardianc trulic taltz
baricitinib could drive upsid potenti
re-rat biotech-lik multipl
slow uptak new diabet immunolog
margin pressur early/intermedi pipelin
failur could caus concern long term
given recent trend commentari updat lilli model notabl see
revenu prior revenu
bottom line see non-gaap ep non-gaap ep
figur detail
million except per share itemspriorcurr chg sell incom expens net ep outstand analysispriorcurr chg chg bp gross sell changepriorcurr chg chg sell million except per share itemspriorcurr chg sell incom expens net ep outstand analysispriorcurr chg chg bp gross sell changepriorcurr chg chg sell barclay eli lilli co
geoff meacham ph herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
avail disclosur
compani subject research report current import disclosur regard compani pleas refer
http //publicresearch barclay com altern send written request barclay research complianc seventh avenu floor
new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ firm total
revenu portion gener invest bank activ profit revenu market busi
potenti interest firm invest client research respect asset class cover analyst
author contribut research report research analyst unless otherwis indic
public date top report reflect local time report produc may differ releas date provid
gmt
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit accept
payment reimburs cover compani travel expens visit
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas refer
procedur pleas
barclay research depart produc variou type research includ limit fundament analysi equity-link analysi
quantit analysi trade idea recommend contain one type barclay research may differ contain
type barclay research whether result differ time horizon methodolog otherwis barclay research depart
oper independ absa research depart absa research produc absa bank limit act corpor
invest bank divis part barclay africa group limit affili invest bank barclay bank plc elig
client may receiv research report research depart may reach differ conclus may contain differ
conflict forecast recommend trade idea
price sourc thomson reuter last avail close price relev trade market unless anoth time sourc
